Prenumeration
Beskrivning
| Land | Finland |
|---|---|
| Lista | First North Finland |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Herantis Pharma Plc | Company Release | December 12, 2024 at 16:00 EET
Herantis Pharma’s financial calendar and annual general meeting for 2025
Herantis Pharma Plc, a company developing disease-modifying therapies for Parkinson’s disease, hereby publishes the financial calendar for 2025.
Financial year 2024:
| Quiet period before 2H and FY 2024 report | February 6 – March 6, 2025 |
| 2H and FY 2024 report | March 6, 2025 |
| Annual report 2024 | March 31, 2025 |
Financial year 2025:
| Deadline for submission of proposal for AGM | March 3, 2025 |
| Annual General Meeting (AGM) | April 24, 2025 |
| Quiet period before 1H 2025 report | July 24 – August 21, 2025 |
| 1H 2025 report | August 21, 2025 |
The dates are subject to change.
For more information, please contact:
Tone Kvåle, CFO
Tel: +47 915 19576
Email: ir@herantis.com
Certified Advisor:
UB Corporate Finance Ltd
Tel.: +358 9 25 380 225
E-mail: ubcf@unitedbankers.fi
About Herantis Pharma Plc
Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096, is an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. It combines the compelling mechanism of action of CDNF with the convenience of subcutaneous administration. The primary aim of the ongoing Phase 1b clinical trial is to show that repeated subcutaneous doses of HER-096 are safe and well-tolerated in patients with Parkinson’s disease. The Phase 1a clinical trial demonstrated a good safety and tolerability profile, and efficient blood-brain barrier penetration of subcutaneously administered HER-096 in healthy volunteers.
The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.
Company website: www.herantis.com